|
[1] YU JJ,YAN WT,QUAN B,et al. Recommendations for EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma(2018)[J]. J Clin Hepatol,2018,34(6):1183-1186.(in Chinese)余炯杰，严文韬，权冰，等．《2018年欧洲肝病学会临床实践指南:肝细胞癌的管理》推荐意见[J]．临床肝胆病杂志，2018,34(6):1183-1186.
|
|
[2] YOON YI,KIM KH,CHO HD,et al. Long-term perioperative outcomes of pure laparoscopic liver resection versus open liver resection for hepatocellular carcinoma:A retrospective study[J]. Surg Endosc,2020,34(2):796-805.
|
|
[3] DI SANDRO S,BAGNARDI V,NAJJAR M,et al. Minor laparoscopic liver resection for hepatocellular carcinoma is safer than minor open resection,especially for less compensated cirrhotic patients:Propensity score analysis[J]. Surg Oncol,2018,27(4):722-729.
|
|
[4] FENG X,SU Y,ZHENG S,et al. A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence[J]. HPB(Oxford),2017,19(8):667-674.
|
|
[5] LI SQ,HUANG T,SHEN SL,et al. Anatomical versus nonanatomical liver resection for hepatocellular carcinoma exceeding Milan criteria[J]. Br J Surg,2017,104(1):118-127.
|
|
[6] TOMIMARU Y,EGUCHI H,MARUBASHI S,et al. Equivalent outcomes after anatomical and non-anatomical resection of small hepatocellular carcinoma in patients with preserved liver function[J]. Dig Dis Sci,2012,57(7):1942-1948.
|
|
[7] SHIMADA S,KAMIYAMA T,ORIMO T,et al. Long-term prognostic factors of patients with hepatocellular carcinoma who survive over 10 years after hepatectomy[J]. J Surg Oncol,2020,121(8):1209-1217.
|
|
[8] FENG AL,ZHU JK,YANG Y,et al. Repeated postoperative adjuvant TACE after curative hepatectomy improves outcomes of patients with HCC[J]. Minim Invasive Ther Allied Technol,2019.[Online ahead of print]
|
|
[9] WANG L,KE Q,DENG M,et al. Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma after radical hepatectomy:A real world study[J]. Scand J Gastroenterol,2019,54(11):1403-1411.
|
|
[10] ZOU H,ZHU CZ,WANG C,et al. Recurrence of barcelona clinic liver cancer stage a hepatocellular carcinoma after hepatectomy[J]. Am J Med Sci,2017,354(3):262-267.
|
|
[11] ZHU H,YE B,QIAO Z,et al. Hepatectomy combined with sorafenib in patients with intermediate-advanced hepatocellullar carcinoma[J]. J BUON,2019,24(4):1382-1389.
|
|
[12] PINYOL R,MONTAL R,BASSAGANYAS L,et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3STORM trial[J]. Gut,2019,68(6):1065-1075.
|
|
[13] Organ Transplantation Branch,Chinese Medical Doctor Association; Chinese Society of Organ Transplantation,Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma(2018)[J]. J Clin Hepatol,2019,35(2):275-280.(in Chinese)中国医师协会器官移植医师分会，中华医学会器官移植学分会．中国肝癌肝移植临床实践指南(2018版)[J]．临床肝胆病杂志，2019,35(2):275-280.
|
|
[14] ZHANG HM,SHI YX,SUN LY,et al. Hepatocellular carcinoma recurrence in living and deceased donor liver transplantation:A systematic review and meta-analysis[J]. Chin Med J(Engl),2019,132(13):1599-1609.
|
|
[15] WONG T,NG K,FUNG J,et al. Long-term survival outcome between living donor and deceased donor liver transplant for hepatocellular carcinoma:Intention-to-treat and propensity score matching analyses[J]. Ann Surg Oncol,2019,26(5):1454-1462.
|
|
[16] YOON YI,LEE SG. Living donor liver transplantation for hepatocellular carcinoma:An asian perspective[J]. Dig Dis Sci,2019,64(4):993-1000.
|
|
[17] HOFFMANN K,GANTEN T,GOTTHARDTP D,et al. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients-a prospective,randomized,double-blind,phase III trial[J]. BMC Cancer,2015,15:392.
|
|
[18] XING M,SAKARIA S,DHANASEKARAN R,et al. Bridging locoregional therapy prolongs survival in patients listed for liver transplant with hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol,2017,40(3):410-420.
|
|
[19] LAI Q,VITALE A,IESARI S,et al. The Intention-to-treat effect of bridging treatments in the setting of milan criteria-in patients waiting for liver transplantation[J]. Liver Transpl,2019,25(7):1023-1033.
|
|
[20] GEISSLER EK,SCHNITZBAUER AA,ZLKE C,et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma:A randomized,multicenter,open-label phase 3 trial[J]. Transplantation,2016,100(1):116-125.
|
|
[21] GRIGG SE,SARRI GL,GOW PJ,et al. Systematic review with meta-analysis:Sirolimus-or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther,2019,49(10):1260-1273.
|
|
[22] HUANG L,LI GM,ZHU JY,et al. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria:A preliminary study[J]. Onco Targets Ther,2012,5:457-462.
|
|
[23] EBARA M,OHTO M,SUGIURA N,et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients[J]. J Gastroenterol Hepatol,1990,5(6):616-626.
|
|
[24] OMATA M,CHENG AL,KOKUDO N,et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:A 2017 update[J]. Hepatol Int,2017,11(4):317-370.
|
|
[25] HU XW,DING TL,HONG ZX. Clinical analysis of partial hepatectomy combined with radiofrequency ablation in the treatment of primary liver cancer[J]. Traum Crit Med,2018,6(4):226-227,230.(in Chinese)胡雄伟，丁同领，洪智贤．部分肝切除术联合射频消融术治疗原发性肝癌疗效分析[J]．创伤与急危重病医学，2018,6(4):226-227,230.
|
|
[26] ZOU H,WU LQ. A propensity score matching analysis of hepatectomy and radiofrequency ablation for patients with solitary hepatocellular carcinoma less than or equal to 5 cm and portal hypertension[J]. Chin J Dig Surg,2018,17(10):1018-1023.(in Chinese)邹浩，吴力群．肝切除术与射频消融术治疗单发肿瘤直径≤5cm肝细胞癌合并门静脉高压症患者的倾向评分匹配疗效分析[J]．中华消化外科杂志，2018,17(10):1018-1023.
|
|
[27] IZZO F,GRANATA V,GRASSI R,et al. Radiofrequency ablation and microwave ablation in liver tumors:An update[J].Oncologist,2019,24(10):e990-990e1005.
|
|
[28] LIAO M,ZHONG X,ZHANG J,et al. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis:A prospective randomized trial[J]. J Surg Oncol,2017,115(8):971-979.
|
|
[29] HUANG JW,YAN L,CHENG ZY,et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria[J]. Ann Surg,2010,252(6):903-912.
|
|
[30] FANG Y,CHEN W,LIANG X,et al. Comparison of longterm effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma[J].J Gastroenterol Hepatol,2014,29(1):193-200.
|
|
[31] LIANG P,WANG Y. Microwave ablation of hepatocellular carcinoma[J]. Oncology,2007,72(Suppl 1):124-131.
|
|
[32] CHONG C,LEE KF,CHEUNG S,et al. Prospective doubleblinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma(McRFA trial)[J]. HPB(Oxford),2020.(Online ahead of print)
|
|
[33] SHI J,SUN Q,WANG Y,et al. Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria[J]. J Gastroenterol Hepatol,2014,29(7):1500-1507.
|
|
[34] FACCIORUSSO A,SERVIDDIO G,MUSCATIELLO N. Local ablative treatments for hepatocellular carcinoma:An updated review[J]. World J Gastrointest Pharmacol Ther,2016,7(4):477-489.
|
|
[35] LITTRUP PJ,AOUN HD,ADAM B,et al. Percutaneous cryoablation of hepatic tumors:Long-term experience of a large U. S. series[J]. Abdom Radiol(NY),2016,41(4):767-780.
|
|
[36] WANG C,WANG H,YANG W,et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma[J]. Hepatology,2015,61(5):1579-1590.
|
|
[37] ZIMMERMAN A,GRAND D,CHARPENTIER KP. Irreversible electroporation of hepatocellular carcinoma:Patient selection and perspectives[J]. J Hepatocell Carcinoma,2017,4:49-58.
|
|
[38] NARAYANAN G. Irreversible electroporation[J]. Semin Intervent Radiol,2015,32(4):349-355.
|
|
[39] STILLSTRM D,BEERMANN M,ENGSTRAND J,et al. Initial experience with irreversible electroporation of liver tumours[J]. Eur J Radiol Open,2019,6:62-67.
|
|
[40] KALRA N,GUPTA P,GORSI U,et al. Irreversible electroporation for unresectable hepatocellular carcinoma:Initial experience[J]. Cardiovasc Intervent Radiol,2019,42(4):584-590.
|
|
[41] CHEUNG TT,FAN ST,CHU SK,et al. Survival analysis of highintensity focused ultrasound ablation in patients with smal hepatocellular carcinoma[J]. HPB(Oxford),2013,15:567-73.
|
|
[42] LI L,TIAN J,LIU P,et al. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma:A meta-analysis[J]. Tumori,2016,2016(3):301-310.
|
|
[43] CHEUNG TT,FAN ST,CHAN SC,et al. High-intensity focused ultrasound ablation:An effective bridging therapy for hepatocellular carcinoma patients[J]. World J Gastroenterol,2013,19(20):3083-3089.
|
|
[44] DI COSTANZO GG,FRANCICA G,PACELLA CM. Laser ablation for small hepatocellular carcinoma:State of the art and future perspectives[J]. World J Hepatol,2014,6(10):704-715.
|
|
[45] ORLACCHIO A,BOLACCHI F,CHEGAI F,et al. Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm[J]. Radiol Med,2014,119(5):298-308.
|
DownLoad: